Langenbeck's Archives of Surgery

, Volume 393, Issue 6, pp 817–824 | Cite as

Clinical sepsis and septic shock—definition, diagnosis and management principles

Current Concepts in Clinical Surgery

Abstract

Introduction

Sepsis remains a common problem in critically ill patients.

Discussion

Considerable advances have been made in our understanding of the pathophysiology of sepsis and recent years have seen a surge of potential new therapeutic agents for sepsis. Definitions have been rethought and strategies proposed to better characterise patients with sepsis as the importance of individually targeted treatment packages has been realised. Current management aims to control infection, to achieve haemodynamic stabilisation, to modulate the immune response and to provide metabolic and organ support. As new therapies are introduced, treatment recommendations will need to be adapted accordingly.

Keywords

Biomarkers Severe sepsis Critically ill Vasopressors Immunomodulation 

References

  1. 1.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310PubMedCrossRefGoogle Scholar
  2. 2.
    Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353PubMedCrossRefGoogle Scholar
  3. 3.
    Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K (2003) Epidemiology of severe sepsis occurring in the first 24hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 31:2332–2338PubMedCrossRefGoogle Scholar
  4. 4.
    Cheng B, Xie G, Yao S, Wu X, Guo Q, Gu M, Fang Q, Xu Q, Wang D, Jin Y, Yuan S, Wang J, Du Z, Sun Y, Fang X (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35:2538–2546PubMedCrossRefGoogle Scholar
  5. 5.
    Zahorec R, Firment J, Strakova J, Mikula J, Malik P, Novak I, Zeman J, Chlebo P (2005) Epidemiology of severe sepsis in intensive care units in the Slovak Republic. Infection 33:122–128PubMedCrossRefGoogle Scholar
  6. 6.
    Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J (2004) Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 30:589–596PubMedCrossRefGoogle Scholar
  7. 7.
    Brun-Buisson C, Meshaka P, Pinton P, Vallet B (2004) EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 30:580–588PubMedCrossRefGoogle Scholar
  8. 8.
    Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606–618PubMedCrossRefGoogle Scholar
  9. 9.
    Silva E, Pedro MA, Sogayar AC, Mohovic T, Silva CL, Janiszewski M, Cal RG, de Sousa EF, Abe TP, de Andrade J, de Matos JD, Rezende E, Assuncao M, Avezum A, Rocha PC, de Matos GF, Bento AM, Correa AD, Vieira PC, Knobel E (2004) Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 8:R251–R260PubMedCrossRefGoogle Scholar
  10. 10.
    Karlsson S, Varpula M, Ruokonen E, Pettila V, Parviainen I, Ala-Kokko TI, Kolho E, Rintala EM (2007) Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 33:435–443PubMedCrossRefGoogle Scholar
  11. 11.
    Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554PubMedCrossRefGoogle Scholar
  12. 12.
    Harrison DA, Welch CA, Eddleston JM (2006) The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 10:R42PubMedCrossRefGoogle Scholar
  13. 13.
    Schottmueller H (1914) Wesen und Behandlung der Sepsis. Inn Med 31:257–280Google Scholar
  14. 14.
    Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ (1992) Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1644–1655PubMedCrossRefGoogle Scholar
  15. 15.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 29:530–538PubMedGoogle Scholar
  16. 16.
    Circiumaru B, Baldock G, Cohen J (1999) A prospective study of fever in the intensive care unit. Intensive Care Med 25:668–673PubMedCrossRefGoogle Scholar
  17. 17.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedCrossRefGoogle Scholar
  18. 18.
    Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, Wong K, Sundin DP, Turlo MA, Janes JM (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit Care Med 33:2266–2277PubMedCrossRefGoogle Scholar
  19. 19.
    Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRefGoogle Scholar
  20. 20.
    Chan YL, Tseng CP, Tsay PK, Chang SS, Chiu TF, Chen JC (2004) Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care 8:R12–R20PubMedCrossRefGoogle Scholar
  21. 21.
    Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL (2003) C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 123:2043–2049PubMedCrossRefGoogle Scholar
  22. 22.
    Ugarte H, Silva E, Mercan D, de Mendonça A, Vincent JL (1999) Procalcitonin as a marker of infection in the intensive care unit. Crit Care Med 27:498–504PubMedCrossRefGoogle Scholar
  23. 23.
    Damas P, Ledoux D, Nys M, Vrindts Y, DeGroote D, Franchimont P, Lamy M (1992) Cytokines serum levels during severe sepsis in human IL6 as a marker of severity. Ann Surg 215:356–362PubMedCrossRefGoogle Scholar
  24. 24.
    Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771–778PubMedGoogle Scholar
  25. 25.
    Pinsky MR, Vincent JL, Deviere J, Alegre M, Schandene L, Kahn RJ, Vandenbussche P, Content J, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple-systems organ failure and mortality. Chest 103:565–575PubMedCrossRefGoogle Scholar
  26. 26.
    Friedman G, Jankowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL (1997) Blood interleukin-10 levels parallel the severity of septic shock. J Crit Care 12:183–187PubMedCrossRefGoogle Scholar
  27. 27.
    Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, Opal S, Abraham E, Brett SJ, Smith T, Mehta S, Derzko A, Romaschin A (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190:527–534PubMedCrossRefGoogle Scholar
  28. 28.
    Toh CH, Ticknor LO, Downey C, Giles AR, Paton RC, Wenstone R (2003) Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation. Intensive Care Med 29:55–61PubMedGoogle Scholar
  29. 29.
    Dempfle CE, Lorenz S, Smolinski M, Wurst M, West S, Houdijk WP, Quintel M, Borggrefe M (2004) Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 32:520–524PubMedCrossRefGoogle Scholar
  30. 30.
    Zakariah AN, Cozzi SM, Van Nuffelen M, Clausi CM, Pradier O, Vincent JL (2008) Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients. Crit Care Med 36(5):1507–1512PubMedCrossRefGoogle Scholar
  31. 31.
    Peres-Bota D, Melot C, Lopes Ferreira F, Vincent JL (2003) Infection probability score (IPS): a simple method to help assess the probability of infection in critically patients. Crit Care Med 31:2579–2584PubMedCrossRefGoogle Scholar
  32. 32.
    Martini A, Gottin L, Mélot C, Vincent JL (2008) A prospective evaluation of the infection probability score (IPS) in the intensive care unit. J Infect 56:313–318Google Scholar
  33. 33.
    Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF (2005) A network-based analysis of systemic inflammation in humans. Nature 437:1032–1037PubMedCrossRefGoogle Scholar
  34. 34.
    Johnson SB, Lissauer M, Bochicchio GV, Moore R, Cross AS, Scalea TM (2007) Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 245:611–621PubMedCrossRefGoogle Scholar
  35. 35.
    Lissauer ME, Johnson SB, Siuzdak G, Bochicchio G, Whiteford C, Nussbaumer B, Moore R, Scalea TM (2007) Coagulation and complement protein differences between septic and uninfected systemic inflammatory response syndrome patients. J Trauma 62:1082–1094PubMedCrossRefGoogle Scholar
  36. 36.
    Carrigan SD, Scott G, Tabrizian M (2004) Toward resolving the challenges of sepsis diagnosis. Clin Chem 50:1301–1314PubMedCrossRefGoogle Scholar
  37. 37.
    Abraham E (2005) Immunological monitoring, functional genomics and proteomics. In: Fink MP, Sibbald WJ, Suter PM (eds) Intensive Care Medicine in 10 Years. Springer, Heidelberg, pp 189–200Google Scholar
  38. 38.
    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60PubMedCrossRefGoogle Scholar
  39. 39.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRefGoogle Scholar
  40. 40.
    Leone M, Bourgoin A, Cambon S, Dubuc M, Albanese J, Martin C (2003) Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 31:462–467PubMedCrossRefGoogle Scholar
  41. 41.
    Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA (2003) Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 123:1615–1624PubMedCrossRefGoogle Scholar
  42. 42.
    Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, Carbajal-Guerrero J, Garcia-Garmendia JL (2008) Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 61:436–441PubMedCrossRefGoogle Scholar
  43. 43.
    Byl B, Clevenbergh P, Jacobs F, Struelens MJ, Zech F, Kentos A, Thys JP (1999) Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy forbacteremia. Clin Infect Dis 29:60–66PubMedCrossRefGoogle Scholar
  44. 44.
    Vincent JL, Weil MH (2006) Fluid challenge revisited. Crit Care Med 34:1333–1337PubMedCrossRefGoogle Scholar
  45. 45.
    Vincent JL, Sakr Y, Sprung CL, Harboe S, Damas P (2008) Are blood transfusions associated with greater mortality rates. Anesthesiology 108:31–39PubMedCrossRefGoogle Scholar
  46. 46.
    Deans KJ, Minneci PC, Suffredini AF, Danner RL, Hoffman WD, Ciu X, Klein HG, Schechter AN, Banks SM, Eichacker PQ, Natanson C (2007) Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med 35:1509–1516PubMedCrossRefGoogle Scholar
  47. 47.
    Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S (2004) Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32:1928–1948PubMedCrossRefGoogle Scholar
  48. 48.
    Grollman A, Geiling EMK (1932) The cardiovascular and metabolic reactions of man to the intramuscular injection of posterior pituitary liquid (Pituitrin), Pitressin and pitochin. J Pharmacol Exp Ther 16:447–460Google Scholar
  49. 49.
    Landry DW, Levin HR, Gallant EM, Ashton RC Jr., Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95:1122–1125PubMedGoogle Scholar
  50. 50.
    Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, Oliver JA (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25:1279–1282PubMedCrossRefGoogle Scholar
  51. 51.
    Malay MB, Ashton RC Jr., Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47:699–703PubMedGoogle Scholar
  52. 52.
    Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA III (2001) Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29:487–493PubMedCrossRefGoogle Scholar
  53. 53.
    Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421PubMedCrossRefGoogle Scholar
  54. 54.
    Rady MY, Rivers EP, Nowak RM (1996) Resuscitation of the critically ill in the ED: responses of blood pressure, heart rate, shock index, central venous oxygen saturation, and lactate. Am J Emerg Med 14:218–225PubMedCrossRefGoogle Scholar
  55. 55.
    Vincent JL, De Backer D (2004) Oxygen transport—the oxygen delivery controversy. Intensive Care Med 30:1990–1996PubMedCrossRefGoogle Scholar
  56. 56.
    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL (2005) Drotrecogin alfa [activated] for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341PubMedCrossRefGoogle Scholar
  57. 57.
    Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369:836–843PubMedCrossRefGoogle Scholar
  58. 58.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedCrossRefGoogle Scholar
  59. 59.
    Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124PubMedCrossRefGoogle Scholar
  60. 60.
    Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patient. N Engl J Med 345:1359–1367PubMedCrossRefGoogle Scholar
  61. 61.
    Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139PubMedCrossRefGoogle Scholar
  62. 62.
    Galban C, Montejo JC, Mesejo A, Marco P, Celaya S, Sanchez-Segura JM, Farre M, Bryg DJ (2000) An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients. Crit Care Med 28:643–648PubMedCrossRefGoogle Scholar
  63. 63.
    Bertolini G, Iapichino G, Radrizzani D, Facchini R, Simini B, Bruzzone P, Zanforlin G, Tognoni G (2003) Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial. Intensive Care Med 29:834–840PubMedCrossRefGoogle Scholar
  64. 64.
    Vincent JL (2007) Metabolic support in sepsis and multiple organ failure: more questions than answers.. Crit Care Med 35:S436–S440PubMedCrossRefGoogle Scholar
  65. 65.
    Zambon M, Ceola M, Castro R, Gullo A, Vincent JL (2008) Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: We could go faster. J Crit Care (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  1. 1.Department of Intensive Care, Erasme University HospitalUniversité libre de BruxellesBrusselsBelgium

Personalised recommendations